Invention Grant
US09593376B2 Natural killer p30 (NKp30) dysfunction and the biological applications thereof
有权
自然杀伤p30（NKp30）功能障碍及其生物应用
- Patent Title: Natural killer p30 (NKp30) dysfunction and the biological applications thereof
- Patent Title (中): 自然杀伤p30（NKp30）功能障碍及其生物应用
-
Application No.: US12994192Application Date: 2009-06-02
-
Publication No.: US09593376B2Publication Date: 2017-03-14
- Inventor: Laurence Zitvogel , Nicolas Delahaye
- Applicant: Laurence Zitvogel , Nicolas Delahaye
- Applicant Address: FR Villejuif FR Paris
- Assignee: INSTITUT GUSTAVE ROUSSY,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
- Current Assignee: INSTITUT GUSTAVE ROUSSY,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
- Current Assignee Address: FR Villejuif FR Paris
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Priority: EP08305223 20080602
- International Application: PCT/EP2009/056741 WO 20090602
- International Announcement: WO2009/147137 WO 20091210
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C07H21/04
Abstract:
The present invention relates to a method of assessing a favorable or, on the contrary, an unfavorable prognosis of a cancer in the subject, which method comprises detecting the presence of a mutated Natural Cytotoxicity-triggering Receptor 3 (NCR3) nucleic acid, an abnormal relative amount of at least one particular Natural Killer p30 (NKp30) RNA transcript isoform, and/or an abnormal Natural Killer p30 (NKp30) expression or activity of at least one particular NKp30 protein isoform in a sample from the subject, the presence of mutated NCR3 nucleic acid, abnormal relative amount of at least one particular NKp30 RNA transcript isoform, or abnormal expression or activity of at least one particular NKp30 protein isoform being indicative of the prognosis of cancer in the subject.
Public/Granted literature
- US20110104136A1 Natural Killer p30 (NKp30) Dysfunction and the Biological Applications Thereof Public/Granted day:2011-05-05
Information query
